Effects of Maternal Symptom Ratings and Other Clinical Features on Short-Term Treatment Response to OROS Methylphenidate in Children and Adolescents with ADHD in a Naturalistic Clinical Setting

ÇÖP, Esra; ÖNER, Özgür; MUNİR, Kerim; YURTBASI, Pinar

Effects of Maternal Symptom Ratings and Other Clinical Features on Short-Term Treatment Response to OROS Methylphenidate in Children and Adolescents with ADHD in a Naturalistic Clinical Setting

Esra ÇÖP, (Yenimahalle Eğitim ve Araştırma Hastanesi, Çocuk ve Ergen Psikiyatrisi Bölümü, Ankara, Türkiye)

Özgür ÖNER, (Ankara Üniveritesi, Ankara Tıp Fakültesi, Çocuk ve Ergen Psikiyatri Anabilim Dalı, Ankara, Türkiye)

Pinar YURTBASI, (İnönü Üniversitesi, Tıp Fakültesi, Turgut Özal Tıp Merkezi, Çocuk Psikiyatrisi Anabilim Dalı, Malatya, Türkiye)

Kerim MUNİR (Harvard Medical School, Childrens Hospital, Boston, MA, USA)

Klinik Psikofarmakoloji Bülteni

0 0

Yıl: 2016 Cilt: 26 Sayı: 2 Sayfa Aralığı: 126 - 133 Metin Dili: İngilizce İndeks Tarihi: 29-07-2022

Effects of Maternal Symptom Ratings and Other Clinical Features on Short-Term Treatment Response to OROS Methylphenidate in Children and Adolescents with ADHD in a Naturalistic Clinical Setting

Öz:

Objective: To investigate the effect of Attention Deficit Hyperactivity Disorder (ADHD), antisocial behavior and anxiety/depression ratings of mothers, and child and adolescents' age, gender, ADHD subtype, and comorbidity on one-month drug treatment response to OROS methylphenidate in ADHD in a naturalistic setting. Methods: The analyses included 223 subjects (191 boys, 32 girls; age 6-15 years, mean: 9.4) treated with OROS methylphenidate (18-72 mg/day, mean: 31 mg/d; 0.4-1.4 mg/kg/d) for one-month. Treatment response was defined as larger than 25% or more decrease in pre-treatment the Conners Parent Rating Scale (CPRS) or the Conners Teacher Rating Scale (CTRS) total scores and the Clinical Global Impression improvement with drug treatment 3 (minimally improved) or higher. Maternal ADHD, antisocial behavior and anxiety/ depression ratings were obtained by the Adult Self Rating (ASR). Logistic regression analyses were computed in order to calculate the effects of gender; age; ADHD subtype; comorbid anxiety disorder, learning disorder, oppositional defiant/conduct disorder; maternal ASR Anxiety/Depression, ADHD and Antisocial scores. Results: 35.2% of subjects had statistically significant 25% or more decrease in pretreatment CPRS total scores and 38.6% of subjects had statistically significant 25% or more decrease in pretreatment CTRS total scores. The subjects with comorbid anxiety disorder had the poorest drug response. Maternal self-reported antisocial and anxiety/depressive symptomatology were statistically significantly associated with worse response to treatment in terms of CPRS (respectively, OR=0.83, 95% CI: 0.75-0.92, p<0.01; OR=0.95, 95% CI: 0.9-0.99, p<0.05) and CTRS total scores (OR=0.9, 95% CI: 0.82-0.99, OR=0.95, 95% CI: 0.91-1, p<0.05). Baseline rating scores were also important predictors of drug treatment response. Effects of age, gender and maternal ADHD were not statistically significant. Conclusion: ADHD children and adolescents with comorbid anxiety disorders and those whose mothers have more self-reports of antisocial and depressive symptoms showed less favorable short-term response to OROS-MPH. These subjects may require further attention and additional interventions to augment treatment with OROS methylphenidate.

Anahtar Kelime:

Konular: Farmakoloji ve Eczacılık

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Swanson JM, Gupta S, Williams L, Agler D, Lerner M, Wigal S. Efficacy of a new pattern of delivery of methylphenidate for the treatment of ADHD: effects on activity level in the classroom and on the playground. J Am Acad Child Adolesc Psychiatry 2002;41(11):1306-14. [CrossRef]
2. Wolraich ML, Greenhill LL, Pelham W, Swanson J, Wilens T, Palumbo D, et al. Randomized, controlled trial of OROS methylphenidate once a day in children with attention deficit/hyperactivity disorder. Pediatrics 2001;108(4):883- 92. [CrossRef]
3. Yildiz-OC O, Agaoglu B, Karakaya I, Sismanlar SG, CakinMemik N. Efficiency and tolerability of OROSmethylphenidate in Turkish children and adolescents with attention-deficit/hyperactivity disorder. Anatolian Journal of Psychiatry 2010;11:44-50. (Turkish)
4. Steele M, Weiss M, Swanson J, Wang J, Prinzo RS, Binder CE. A randomized, controlled, effectiveness trial of OROSmethylphenidate compared to usual care with immediaterelease methylphenidate in attention deficit- hyperactivity disorder. Can J Clin Pharmacol 2006;13(1):e50-62.
5. Akyol-Ardic U, Ercan ES, Ercan E, Yuce D, Kabukcu-Basay B. Osmotic release oral system methylphenidate is more effective than immediate release methylphenidate: a retrospective chart review in Turkish children with attention deficit hyperactivity disorder. Klinik Psikofarmakoloji Bulteni-Bulletin of Clinical Psychopharmacology 2014;24(4):342-9. [CrossRef]
6. Owens EB, Hinshaw SP, Kraemer HC, Arnold LE, Abikoff HB, Cantwell DP, et al. Which treatment for whom for ADHD? Moderators of treatment response in the MTA. J Consult Clin Psychol 2003;71(3):540 -52. [CrossRef]
7. Alsen S, Resmi H, Ozek H, Tufan AE , Bulbul M, Pekcanlar AA. Plasma norepinephrine and dopamine levels in prepubertal male children with attention-deficit hyperactivity disorder do not change with 8 weeks of methylphenidate treatment Klinik Psikofarmakoloji Bulteni - Bulletin of Clinical Psychopharmacology 2015;25(3):259- 66. [CrossRef]
8. Stein MA, Sarampote CS, Waldman ID, Robb AS, Conlon C, Pearl PL, et al. A dose-response study of OROS methylphenidate in children with attention-deficit/ hyperactivity disorder. Pediatrics 2003;112(5):e404. [CrossRef]
9. Gorman EB, Klorman R, Thatcher JE, Borgstedt AD. Effects of methylphenidate on subtypes of attention-deficit/ hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2006;45(7):808-16. [CrossRef]
10. Solanto M, Newcorn J, Vail L, Gilbert S, Ivanov I, Lara R. Stimulant drug response in the predominantly inattentive and combined subtypes of attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2009;19(6):663- 71. [CrossRef]
11. Nigg JT, Hinshaw SP. Parent personality traits and psychopathology associated with antisocial behaviors in childhood attention-deficit hyperactivity disorder. J Child Psychol Psychiatry 1998;39(2):145-59. [CrossRef]
12. Chronis AM, Lahey BB, Pelham WE Jr, Kipp HL, Baumann BL, Lee SS. Psychopathology and substance abuse in parents of young children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2003;42(12):1424-32. [CrossRef]
13. Faraone SV, Biederman J, Jetton JG, Tsuang MT. Attention deficit disorder and conduct disorder: longitudinal evidence for a familial subtype. Psychol Med 1997;27(2):291-300. [CrossRef]
14. Jensen PS, Hinshaw SP, Swanson JM, Greenhill LL, Conners CK, Arnold LE, et al. Findings from the NIMH multimodal treatment study of ADHD (MTA): implications and applications for primary care providers. J Dev Behav Pediatr 2001;22(1):60-73. [CrossRef]
15. Sonuga-Barke EJ, Daley D, Thompson M. Does maternal ADHD reduce the effectiveness of parent training for preschool children's ADHD? J Am Acad Child Adolesc Psychiatry 2002;41(6):696-702. [CrossRef]
16. Gokler B, Unal F, Pehlivanturk B, Kultur EC, Akdemir D, Taner Y. Reliability and validity of schedule for affective disorders and schizophrenia for school age children-present and lifetime version-Turkish version (K-SADS-PL-T). Turkish Journal of Child and Adolescent Mental Health 2004;11(3):109-16. (Turkish)
17. Conners CK. Conners' Rating Scales- Revised. Multi-Health Systems Publishing, North Tonawada, NY,1997.
18. Dereboy C, Senol S, Sener S. Adaptation of Conners' parent rating scale in Turkish. In: Proceedings 10th National Congress of Psychology. Ankara, Turkey, 1998.
19. Goyette CH, Conners CK, Ulrich RF. Normative data on revised Conners' parent and teacher rating scales. J Abnorm Child Psychol 1978;6(2):221-36. [CrossRef]
20. Sener S, Dereboy C, Dereboy IF, Sertcan Y. Conners' teacher rating scale Turkish version-I. Turkish Journal of Child and Adolescent Mental Health 1995;2(3):131-41. (Turkish)
21. Achenbach TM, Rescorla LA. Manual for the ASEBA Adult Forms & Profiles. Burlington, VT: University of Vermont, Research Center for Children, Youth, & Families, 2003.
22. Guy W. ECDEU Assessment Manual for Psychopharmacology --Revised (DHEW Publ No ADM 76-338). Rockville, MD, U.S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976. p.218-22.
23. Kazdin AE. Parent management training: evidence, outcomes, and issues. J Am Acad Child Adolesc Psychiatry 1997;36(10):1349-56. [CrossRef]
24. Buitelaar JK, Van der Gaag RJ, Swaab-Barneveld H, Kuiper M. Prediction of clinical response to methylphenidate in children with attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1995;34(8):1025-32. [CrossRef]
25. Gray JR, Kagan J. The challenge of predicting which children with attention deficit-hyperactivity disorder will respond positively to methylphenidate. J Appl Dev Psychol 2000;21(5):471-89. [CrossRef]
26. Pliszka SR. Effects of anxiety on cognition, behavior and stimulant response in ADHD. J Am Acad Child Adolesc Psychiatry 1989;28(6):882-7. [CrossRef]
27. Taylor E, Schachar R, Thorley G, Wieselberg HM, Everitt B, Rutter M. Which boys respond to stimulant medication? a controlled trial of methylphenidate in boys with disruptive behavior. Psychol Med 1987;17(1):121-43. [CrossRef]
28. March JS, Swanson JM, Arnold LE, Hoza B, Conners CK, Hinshaw SP, et al. Anxiety as a predictor and outcome variable in the multimodal treatment study of children with ADHD (MTA). J Abnorm Child Psychol 2000;28(6):527-41. [CrossRef]
29. Jensen PS, Arnold LE, Swanson JM, Vitiello B, Abikoff HB, Greenhill LL, et al. 3-year follow-up of the NIMH MTA study. J Am Acad Child Adolesc Psychiatry 2007;46(8):989-1002. [CrossRef]
30. Chazan R, Borowski C, Pianca T, Ludwig H, Rohde LA, Polanczyk G. Do phenotypic characteristics, parental psychopathology, family functioning, and environmental stressors have a role in the response to methylphenidate in children with attention-deficit/hyperactivity disorder? A naturalistic study from a developing country. J Clin Psychopharmacol 2011;31(3):309-17. [CrossRef]

APA	ÇÖP E, ÖNER Ö, YURTBASI P, MUNİR K (2016). Effects of Maternal Symptom Ratings and Other Clinical Features on Short-Term Treatment Response to OROS Methylphenidate in Children and Adolescents with ADHD in a Naturalistic Clinical Setting. , 126 - 133.
Chicago	ÇÖP Esra,ÖNER Özgür,YURTBASI Pinar,MUNİR Kerim Effects of Maternal Symptom Ratings and Other Clinical Features on Short-Term Treatment Response to OROS Methylphenidate in Children and Adolescents with ADHD in a Naturalistic Clinical Setting. (2016): 126 - 133.
MLA	ÇÖP Esra,ÖNER Özgür,YURTBASI Pinar,MUNİR Kerim Effects of Maternal Symptom Ratings and Other Clinical Features on Short-Term Treatment Response to OROS Methylphenidate in Children and Adolescents with ADHD in a Naturalistic Clinical Setting. , 2016, ss.126 - 133.
AMA	ÇÖP E,ÖNER Ö,YURTBASI P,MUNİR K Effects of Maternal Symptom Ratings and Other Clinical Features on Short-Term Treatment Response to OROS Methylphenidate in Children and Adolescents with ADHD in a Naturalistic Clinical Setting. . 2016; 126 - 133.
Vancouver	ÇÖP E,ÖNER Ö,YURTBASI P,MUNİR K Effects of Maternal Symptom Ratings and Other Clinical Features on Short-Term Treatment Response to OROS Methylphenidate in Children and Adolescents with ADHD in a Naturalistic Clinical Setting. . 2016; 126 - 133.
IEEE	ÇÖP E,ÖNER Ö,YURTBASI P,MUNİR K "Effects of Maternal Symptom Ratings and Other Clinical Features on Short-Term Treatment Response to OROS Methylphenidate in Children and Adolescents with ADHD in a Naturalistic Clinical Setting." , ss.126 - 133, 2016.
ISNAD	ÇÖP, Esra vd. "Effects of Maternal Symptom Ratings and Other Clinical Features on Short-Term Treatment Response to OROS Methylphenidate in Children and Adolescents with ADHD in a Naturalistic Clinical Setting". (2016), 126-133.

APA	ÇÖP E, ÖNER Ö, YURTBASI P, MUNİR K (2016). Effects of Maternal Symptom Ratings and Other Clinical Features on Short-Term Treatment Response to OROS Methylphenidate in Children and Adolescents with ADHD in a Naturalistic Clinical Setting. Klinik Psikofarmakoloji Bülteni, 26(2), 126 - 133.
Chicago	ÇÖP Esra,ÖNER Özgür,YURTBASI Pinar,MUNİR Kerim Effects of Maternal Symptom Ratings and Other Clinical Features on Short-Term Treatment Response to OROS Methylphenidate in Children and Adolescents with ADHD in a Naturalistic Clinical Setting. Klinik Psikofarmakoloji Bülteni 26, no.2 (2016): 126 - 133.
MLA	ÇÖP Esra,ÖNER Özgür,YURTBASI Pinar,MUNİR Kerim Effects of Maternal Symptom Ratings and Other Clinical Features on Short-Term Treatment Response to OROS Methylphenidate in Children and Adolescents with ADHD in a Naturalistic Clinical Setting. Klinik Psikofarmakoloji Bülteni, vol.26, no.2, 2016, ss.126 - 133.
AMA	ÇÖP E,ÖNER Ö,YURTBASI P,MUNİR K Effects of Maternal Symptom Ratings and Other Clinical Features on Short-Term Treatment Response to OROS Methylphenidate in Children and Adolescents with ADHD in a Naturalistic Clinical Setting. Klinik Psikofarmakoloji Bülteni. 2016; 26(2): 126 - 133.
Vancouver	ÇÖP E,ÖNER Ö,YURTBASI P,MUNİR K Effects of Maternal Symptom Ratings and Other Clinical Features on Short-Term Treatment Response to OROS Methylphenidate in Children and Adolescents with ADHD in a Naturalistic Clinical Setting. Klinik Psikofarmakoloji Bülteni. 2016; 26(2): 126 - 133.
IEEE	ÇÖP E,ÖNER Ö,YURTBASI P,MUNİR K "Effects of Maternal Symptom Ratings and Other Clinical Features on Short-Term Treatment Response to OROS Methylphenidate in Children and Adolescents with ADHD in a Naturalistic Clinical Setting." Klinik Psikofarmakoloji Bülteni, 26, ss.126 - 133, 2016.
ISNAD	ÇÖP, Esra vd. "Effects of Maternal Symptom Ratings and Other Clinical Features on Short-Term Treatment Response to OROS Methylphenidate in Children and Adolescents with ADHD in a Naturalistic Clinical Setting". Klinik Psikofarmakoloji Bülteni 26/2 (2016), 126-133.